Psyence BioMed has formalized a put option agreement with PsyLabs, a pharmaceutical-grade psychedelic manufacturer, following board approval. The arrangement grants PsyLabs the contractual right to require Psyence to increase its equity stake in the supplier, while simultaneously ensuring Psyence maintains reliable access to pharmaceutical-grade psychedelics for its clinical development and commercial initiatives.
The structure addresses a critical need within the emerging psychedelic pharmaceutical sector: securing consistent supply of regulated, high-quality active pharmaceutical ingredients. By utilizing a put option framework, the agreement allows PsyLabs to trigger additional capital contributions from Psyence when needed, while protecting Psyence's immediate liquidity position.
The arrangement represents a strategic approach to managing both supply chain resilience and near-term capital requirements as Psyence advances its psychedelic-based therapeutic programs through development stages. This type of tiered investment structure has become increasingly common in biotech partnerships where supply security and financial flexibility are both critical considerations.